By Connor Hart
Shares of Mineralys Therapeutics gained after the company said it plans to release data from two recent trials involving lorundrostat, a drug the company is developing as a treatment for high blood pressure.
The stock was up 13%, to $11.88, in after-hours trading Friday. Shares ended the regular session roughly flat and have lost a quarter of their value in the past year.
The Radnor, Pa., biopharmaceutical company said after the bell that it would host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday morning.
The Launch-HTN trial evaluated lorundrostat as an add-on therapy to an existing, prescribed background treatment of two-to-five anti-hypertensive medications, while the Advance-HTN trial evaluated the drug as an add-on therapy to a standardized background treatment of two or three anti-hypertensive medications, the company said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 07, 2025 17:52 ET (22:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.